抗精神病药临床试验终点定义与试验时长的关联
结果显示治疗1周后药物与安慰剂应答已显著分离,第4周各治疗组总体一致率达93.0%;改良PANSS与总PANSS变化的一致率在第4周为93.0%、第6周为97.7%。缩短至4周需样本量502人,采用改良PANSS终点时4周试验需402人、6周试验需296人。
要点
- 治疗1周后药物与安慰剂应答即显著分离,第4周各治疗组总体一致率达93.0%。
- 改良PANSS与总PANSS变化的一致率第4周为93.0%、第6周为97.7%。
- 缩短试验至4周需样本量502人,采用改良PANSS终点时4周需402人、6周需296人。
核心结论
- 分析结果提示有可能优化精神分裂症药物临床试验的设计,申办方应考虑采纳这些策略并尽早咨询FDA。
主要发现
- 药物治疗1周后与安慰剂的应答出现统计学显著分离。
- 各治疗组总体一致率从第1周至第4周稳步上升:第1周68.0%、第2周74.0%、第3周83.0%、第4周93.0%。
- 不良事件趋势在第1周已显现,第3、4、6周不良事件百分比相似。
- 改良PANSS与总PANSS基线变化的一致率在第4周为93.0%(80/86治疗组)、第6周为97.7%(84/86治疗组)。
关键数值与推荐
- 缩短试验至4周所需样本量为502名受试者。
- 采用改良PANSS作为终点时,4周试验所需样本量为402名受试者,6周试验为296名受试者。
临床怎么用
- 申办方在精神分裂症药物临床试验设计中可考虑缩短试验时长至4周并采用改良PANSS作为终点,但需在药物开发早期与FDA沟通。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Facilitating the development of safe and effective medications for schizophrenia is a public health imperative. OBJECTIVES: To evaluate the association of shortening randomized clinical trial (RCT) duration with the modification of the Positive and Negative Syndrome Scale (PANSS) for the design of RCTs of medications for schizophrenia and to offer perspective on an alternative regulatory pathway to the historically accepted trial duration and response assessment. DATA SOURCES: A database was created consisting of clinical trial data from 32 placebo-controlled RCTs of 8 atypical antipsychotic drugs approved by the US Food and Drug Administration (FDA) between January 1, 2001, and December 31, 2015. The database included information on total and individual PANSS item ratings, demographic characteristics, disposition, and adverse events (AEs). STUDY SELECTION: All clinical trials submitted to 8 new drug applications of atypical antipsychotic drugs were selected. DATA EXTRACTION AND SYNTHESIS: Quality control checks were performed to ensure that the collected data were consistent with the reported results of each trial. Data were collected from March 15, 2015, to September 30, 2015. Data analysis was conducted from October 1, 2015, to June 20, 2016. MAIN OUTCOMES AND MEASURES: The following analyses were performed: (1) longitudinal assessment of mean change from baseline in total PANSS score, (2) correlation analyses between change from baseline in total PANSS score at week 6 and earlier time points, (3) concordance analyses of outcomes across trials between week 6 and earlier time points using total PANSS and modified PANSS, and (4) analyses of time course of treatment-emergent AEs. RESULTS: The final database contained data from 14 219 participants enrolled in 32 drug trials; 9805 of 14 219 participants (69.0%) were male and were either white (7183 [50.5%]) or black (4346 [30.6%]) individuals. The mean (SD) age during treatment was 38.9 (10.9) years, and the mean (SD) age at schizophrenia diagnosis was 25 (8.5) years. Statistically significant separation between treatment response and placebo response was observed after 1 week of treatment. The overall concordance rate across treatment groups steadily increased from week 1 to week 4 (68.0% for week 1, 74.0% for week 2, 83.0% for week 3, and 93.0% for week 4). Trends in AE occurrence were evident by week 1 and percentage of AEs were similar across weeks 3, 4, and 6. The overall concordance rate between change from baseline in the modified PANSS score and change from baseline in the total PANSS score was 93.0% (80 of 86 treatment groups) at week 4 and 97.7% (84 of 86 treatment groups) at week 6. Shortening the trial duration to 4 weeks increased the required sample size to 502 participants. Using the modified PANSS as the end point, the sample size for a 4-week trial was 402 participants and 296 participants for a 6-week trial. CONCLUSIONS AND RELEVANCE: Findings from this analysis suggest that there is the potential to streamline the design of schizophrenia drug clinical trials. Trial sponsors may consider incorporating these strategies and are encouraged to consult with the FDA early in the drug development process.
引用
- Younis IR, Gopalakrishnan M, Mathis M, et al. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications. JAMA Psychiatry. 2020. PMID: 32609294. doi:10.1001/jamapsychiatry.2020.1596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。